This is a news story, published by PBS, that relates primarily to Miles O'Brien news.
For more Miles O'Brien news, you can click here:
more Miles O'Brien newsFor more mental health treatments news, you can click here:
more mental health treatments newsFor more news from PBS, you can click here:
more news from PBSOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
psychedelic drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Caleb Hellerman news, key FDA advisory committee news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDAPBS
•
65% Informative
The FDA must now decide whether it will reject the use of what's known as MDMA .
Some patients and researchers had long hoped the government would approve it.
Miles O'Brien is a veteran, independent journalist who focuses on science, technology and aerospace.
Caleb Hellerman is a reporter, writer and filmmaker with the Global Health Reporting Center .
VR Score
59
Informative language
52
Neutral language
96
Article tone
formal
Language
English
Language complexity
58
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links